Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 11/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17846117 | 0.93 | MAPK1 (0.41) | MAPK1TLR8TLR7SRCABL1 | |
| SCHEMBL17846098 | 0.90 | MAPT (0.42) | MAPK1 | |
| SCHEMBL19348994 | 0.84 | TLR8 (0.41) | MAPK1TLR8TLR7SRCABL1 | |
| SCHEMBL17845997 | 0.84 | MAPK1 (0.53) | MAPK1TACR3 | |
| SCHEMBL17846165 | 0.77 | MAPK1 (0.51) | MAPK1TACR3 | |
| SCHEMBL17846227 | 0.75 | MAPK1 (0.44) | MAPK1 | |
| SCHEMBL17846110 | 0.75 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL17846131 | 0.75 | MAPK1 (0.49) | MAPK1 | |
| SCHEMBL17846219 | 0.75 | MAPK1 (0.45) | MAPK1TACR3 | |
| SCHEMBL17846185 | 0.73 | MAPK1 (0.42) | MAPK1GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233859-B1 | BRIDGED PYRAZOLOPYRIDINE DERIVATIVES AS ERK INHIBITORS USEFUL FOR THE TREATEMENT OF CANCER | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9988397-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3233859-A1 | ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170267695-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| WO-2016100051-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267695-A1 | ERK INHIBITORS | MAPK1, MAP3K1, MAPK4 | MAPK1 1/4885TLR8 3917/4885TLR7 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.